BioMAdvanced Diagnostics

BioMAdvanced Diagnostics is a MedTech start-up that aims to provide "hybrid" molecular diagnostic tests and biomarkers related to the immune response of patients. On the basis of a common technological base, the first applications will concern: 1) improving the follow-up of patients who have received a kidney or lung transplant, 2) determining the best drug to administer to patients suffering from ulcerative colitis (UC), and 3) detrmining in advance if patients treated for cancer or kidney disease (dialysis) are about to develop muscular atrophy or not. These tests are designed to be integrated into standard diagnostic and treatment protocols, easy to use by the staff in charge of the targeted patients. Predictive scores are produced using algorithms based on the combination of signatures from the expression of selected genes and clinical parameters.

The tests will be offered for sale in the form of "hybrid" products consisting of both a physical qPCR analysis kit and access to a cloud server hosting the algorithm allowing the finalization and interpretation of the composite score. This score will be used by the clinician to guide his/her action.

The benefits are two-fold: 1.  Organizational innovation for hospitals with a simplification of follow-up protocols and 2. Innovation for clinicians, as, in the standard of care, they try to make decisions without appropriate information, or in case of the transplant patients, through biopsies, which are invasive, risky and expensive.

The company is led by a very senior team who has been delivering consistently against the plan.